Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Evidence that the plant cannabinoid cannabigerol is a highly potent alpha2-adrenoceptor agonist and moderately potent 5HT1A receptor antagonist.

Cascio MG, Gauson LA, Stevenson LA, Ross RA, Pertwee RG.

Br J Pharmacol. 2010 Jan;159(1):129-41. doi: 10.1111/j.1476-5381.2009.00515.x. Epub 2009 Dec 4.

2.

Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.

Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, Pertwee RG.

Br J Pharmacol. 2005 Dec;146(7):917-26.

3.

The psychoactive plant cannabinoid, Delta9-tetrahydrocannabinol, is antagonized by Delta8- and Delta9-tetrahydrocannabivarin in mice in vivo.

Pertwee RG, Thomas A, Stevenson LA, Ross RA, Varvel SA, Lichtman AH, Martin BR, Razdan RK.

Br J Pharmacol. 2007 Mar;150(5):586-94. Epub 2007 Jan 22.

4.

O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties.

Pertwee RG, Gibson TM, Stevenson LA, Ross RA, Banner WK, Saha B, Razdan RK, Martin BR.

Br J Pharmacol. 2000 Apr;129(8):1577-84.

5.

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.

Thomas A, Baillie GL, Phillips AM, Razdan RK, Ross RA, Pertwee RG.

Br J Pharmacol. 2007 Mar;150(5):613-23. Epub 2007 Jan 22.

6.

The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice.

Bolognini D, Costa B, Maione S, Comelli F, Marini P, Di Marzo V, Parolaro D, Ross RA, Gauson LA, Cascio MG, Pertwee RG.

Br J Pharmacol. 2010 Jun;160(3):677-87. doi: 10.1111/j.1476-5381.2010.00756.x.

7.

In vitro and in vivo profiling of fadolmidine, a novel potent alpha(2)-adrenoceptor agonist with local mode of action.

Lehtimäki J, Leino T, Koivisto A, Viitamaa T, Lehtimäki T, Haapalinna A, Kuokkanen K, Virtanen R.

Eur J Pharmacol. 2008 Dec 3;599(1-3):65-71. doi: 10.1016/j.ejphar.2008.10.003. Epub 2008 Oct 9.

PMID:
18930723
8.

The bioassay of cannabinoids using the mouse isolated vas deferens.

Thomas A, Pertwee RG.

Methods Mol Med. 2006;123:191-207.

PMID:
16506409
9.

Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens.

Pertwee RG, Thomas A, Stevenson LA, Maor Y, Mechoulam R.

Neuropharmacology. 2005 Jun;48(8):1139-46. Epub 2005 Mar 19.

PMID:
15910889
10.

6"-Azidohex-2"-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist.

Thomas A, Ross RA, Saha B, Mahadevan A, Razdan RK, Pertwee RG.

Eur J Pharmacol. 2004 Mar 8;487(1-3):213-21.

PMID:
15033394
11.

In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.

Cascio MG, Bisogno T, Palazzo E, Thomas A, van der Stelt M, Brizzi A, de Novellis V, Marabese I, Ross R, van de Doelen T, Brizzi V, Pertwee R, Maione S, Di Marzo V.

Br J Pharmacol. 2006 Oct;149(4):431-40. Epub 2006 Sep 4.

12.

(-)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens.

Pertwee RG, Ross RA, Craib SJ, Thomas A.

Eur J Pharmacol. 2002 Dec 5;456(1-3):99-106.

PMID:
12450575
14.

Pharmacological characterisation of cannabinoid CB(1) receptors in the rat and mouse.

Lay L, Angus JA, Wright CE.

Eur J Pharmacol. 2000 Mar 10;391(1-2):151-61.

PMID:
10720647
15.

AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor.

Bolognini D, Cascio MG, Parolaro D, Pertwee RG.

Br J Pharmacol. 2012 Apr;165(8):2561-74. doi: 10.1111/j.1476-5381.2011.01503.x.

16.

Novel selective cannabinoid CB(1) receptor antagonist MJ08 with potent in vivo bioactivity and inverse agonistic effects.

Chen W, Xu C, Liu HY, Long L, Zhang W, Zheng ZB, Xie YD, Wang LL, Li S.

Acta Pharmacol Sin. 2011 Sep;32(9):1148-58. doi: 10.1038/aps.2011.80. Epub 2011 Aug 15.

17.

3-Substituted pyrazole analogs of the cannabinoid type 1 (CB₁) receptor antagonist rimonabant: cannabinoid agonist-like effects in mice via non-CB₁, non-CB₂ mechanism.

Wiley JL, Selley DE, Wang P, Kottani R, Gadthula S, Mahadeven A.

J Pharmacol Exp Ther. 2012 Feb;340(2):433-44. doi: 10.1124/jpet.111.187815. Epub 2011 Nov 15.

18.

Δ8-Tetrahydrocannabivarin prevents hepatic ischaemia/reperfusion injury by decreasing oxidative stress and inflammatory responses through cannabinoid CB2 receptors.

Bátkai S, Mukhopadhyay P, Horváth B, Rajesh M, Gao RY, Mahadevan A, Amere M, Battista N, Lichtman AH, Gauson LA, Maccarrone M, Pertwee RG, Pacher P.

Br J Pharmacol. 2012 Apr;165(8):2450-61. doi: 10.1111/j.1476-5381.2011.01410.x.

19.

Characterization of cannabinoid receptor ligands in tissues natively expressing cannabinoid CB2 receptors.

Marini P, Cascio MG, King A, Pertwee RG, Ross RA.

Br J Pharmacol. 2013 Jun;169(4):887-99. doi: 10.1111/bph.12191.

20.

Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens.

Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, Pertwee RG.

Br J Pharmacol. 2001 Feb;132(3):631-40.

Supplemental Content

Support Center